Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | FURIN | P09958 | 7/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.34 |
| ▸ | Q9HBH1 | 1/20 | 0.34 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23393940 | 0.88 | SIRT5 (0.39) | NPY4RNPY1RFURINC3AR1 | |
| SCHEMBL21915057 | 0.86 | C3AR1 (0.34) | FURINC3AR1 | |
| SCHEMBL20795891 | 0.86 | FURIN (0.36) | NPY4RNPY1RFURINC3AR1 | |
| SCHEMBL20159819 | 0.86 | FURIN (0.36) | NPY4RNPY1RFURINC3AR1 | |
| SCHEMBL23736705 | 0.86 | FURIN (0.36) | NPY4RNPY1RFURINC3AR1 | |
| SCHEMBL1711524 | 0.86 | C3AR1 (0.44) | FOLH1FURINC3AR1 | |
| SCHEMBL22001947 | 0.86 | C3AR1 (0.34) | FURINC3AR1 | |
| SCHEMBL24490420 | 0.86 | C3AR1 (0.34) | FURINC3AR1 | |
| SCHEMBL21103418 | 0.86 | SIRT5 (0.36) | NPY4RNPY1RFURINC3AR1 | |
| SCHEMBL20375788 | 0.86 | SIRT5 (0.36) | NPY4RNPY1RFURINC3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170182181-A1 | PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182181-A1 | PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES | CD47, PLPBP, CHERP | FOLH1 66/4885MAPT 675/4885HSD17B10 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.